[1] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版)[J]. 中华消化外科杂志,2022,21(2):143-168. [2] Zhong JH, Ke Y, Gong WF, et al.Hepatic resection associated with good survival for selected patients with intermediate and ad- vanced-stage hepatocellular carcinoma[J]. Ann Surg, 2014, 260(2): 329-340. [3] 符雨嫣,金春林,孙辉,等. 晚期肝癌一线系统治疗药品的临床综合评价[J]. 临床药物治疗杂志,2021,19(10):66-70. [4] Llovet JM, Ricci S,Mazzaferro V,et al.Sorafenib in advanced hepato-cellular carcinoma[J]. N Engl J Med,2008,359(4):378-390. [5] Kudo M,Finn RS,Qin S,et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:a randomised phase 3 non-inferiority trial[J]. Lancet,2018,391(10126):1163-1173. [6] El-Khoueiry AB,Sangro B,Yau T,et al.Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040):an open-label,non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017,389(10088):2492-2502. [7] Zhu AX,Finn RS,Edeline J,et al.Pembrolizumab in patients with advanced hepatocellular carcinomapreviously treated with sorafenib(KEYNOTE-224):a non-randomised, open-label phase 2 trial[J]. Lancet Oncol,2018,19(7):940-952. [8] Yau T, Park JW, Finn RS, et al.Nivolumab versus sorafenib in advanced hepatocellular carcinoma(CheckMate 459):a randomised, mul- ticentre , open-label,phase 3trial[J]. Lancet Oncol,2022,23(1):77-90. [9] Finn RS, Ryoo BY, Merle P, et al.Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240:A Randomized, Double-Blind, PhaseⅢ Trial[J]. J Clin Oncol,2020,38(3):193-202. [10] Qin S, Chan SL, Gu S, et al.Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study[J]. Lancet, 2023, 402(10408):1133-1146. [11] Finn RS, Qin S,Ikeda M,et al.IMbrave150:Updated overall survival(OS) data from a global,randomized, open-label phase II study of atezolizumab(atezo) +bevacizumab (bev) versus sorafenib (sor) in patients(pts) with unresectable hepatocellular carcinoma(HCC)[J]. J Clin Oncol,2021,39(3_suppl):267. [12] Finn RS,Kudo M, Merle P,et al.LBA34 Primary results from the phase I LEAP-002study:Lenvatinib plus pembrolizumab versus lenvatinib as first-line(1L) therapy for advanced hepatocellular carcinoma (aHCC)[J]. Ann Oncol,2022,33(suppl_7):S808-S869. [13] Patel SA, Minn AJ.Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies[J]. Immunity, 2018, 48(3):417-433. [14] Gravett AM, Trautwein N, Stevanovic S, et al.Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells[J]. Oncoimmunology, 2018, 7(6):e1438107. [15] Welters MJ,vanderSluis TC,vanMeir H,etal.Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses[J]. Sci Transl Med, 2016,8(334):334ra52. [16] Park SE,Lee SH,Ahn JS,et al.Increased response rates to salvage chemotherapy administered after PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer[J]. J Thorac Oncol, 2018,13(1):106-111. [17] Wang M,Yao X,Bo Z,et al.Synergistic Effect of Lenvatinib and Chemotherapyin Hepatocellular Carcinoma Using Preclinical Models[J]. J Hepato Cell Carcinoma, 2023,10:483-495. [18] Lai Z,He M,Bu X,et al.Lenvatinib,toripalimab plus hepatic arterial infusion chemother apyin patients with high-risk advanced hepatocellular carcinoma:A biomolecular exploratory,phase II trial[J]. Eur J Cancer,2022,174:68-77. [19] Zhang L,Feng D,Yu LX,et al.Preexisting antitumor immunity augments the antitumor effects of chemotherapy[J]. Cancer Immunol Immunother,2013,62(6):1061-1071. [20] 中国抗癌协会肝癌专业委员会转化治疗协作组.肝癌转化治疗中国专家共识(2021版)[J]. 中国实用外科杂志,2021,41(6):618-632. [21] 陈亚进. 肝癌转化治疗现状与思考[J]. 中国实用外科杂志,2021,41(3):253-256,261. [22] Xu L. Transarterial infusion chemotherapy(TAI)combined with sintilimab in locally advanced,potentially resectable hepatocellular carcinoma(HCC)[R/OL].(2020-05-01)[2020-12-01].https://meetinglibrary.asco.org/record/186584/abstract. [23] Zhou H,Song T.Conversion therapy and maintenance therapy for primary hepatocellular carcinoma[J]. Biosci Trends,2021,15(3):155-160. |